Lexeo Current Deferred Revenue vs Accounts Payable Analysis
| LXEO Stock | 7.83 0.50 6.82% |
Lexeo Therapeutics, financial indicator trend analysis is infinitely more than just investigating Lexeo Therapeutics, recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lexeo Therapeutics, is a good investment. Please check the relationship between Lexeo Therapeutics, Current Deferred Revenue and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexeo Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
Current Deferred Revenue vs Accounts Payable
Current Deferred Revenue vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lexeo Therapeutics, Current Deferred Revenue account and Accounts Payable. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Lexeo Therapeutics,'s Current Deferred Revenue and Accounts Payable is 0.82. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Lexeo Therapeutics, Common, assuming nothing else is changed. The correlation between historical values of Lexeo Therapeutics,'s Current Deferred Revenue and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Lexeo Therapeutics, Common are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Current Deferred Revenue i.e., Lexeo Therapeutics,'s Current Deferred Revenue and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.82 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Accounts Payable
An accounting item on the balance sheet that represents Lexeo Therapeutics, obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Lexeo Therapeutics, are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Lexeo Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lexeo Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexeo Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. As of the 28th of November 2024, Sales General And Administrative To Revenue is likely to grow to 17.34, while Selling General Administrative is likely to drop about 9.7 M.
| 2010 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 13.4K | 1.1M | 1.8M | 1.1M | Interest Income | 15K | 1.3M | 2.9M | 1.5M |
Lexeo Therapeutics, fundamental ratios Correlations
Click cells to compare fundamentals
Lexeo Therapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with Lexeo Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexeo Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving together with Lexeo Stock
| 0.69 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.85 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.79 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Lexeo Stock
| 0.81 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.66 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.36 | MNOV | MediciNova | PairCorr |
| 0.34 | PHVS | Pharvaris BV | PairCorr |
The ability to find closely correlated positions to Lexeo Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexeo Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexeo Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexeo Therapeutics, Common to buy it.
The correlation of Lexeo Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexeo Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexeo Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexeo Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexeo Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.53) | Return On Assets (0.40) | Return On Equity (0.75) |
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexeo Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.